Celgene Drops GED-0301 as Crohn’s Therapy but Will Continue Testing It for Ulcerative Colitis

Celgene Drops GED-0301 as Crohn’s Therapy but Will Continue Testing It for Ulcerative Colitis
Celgene Corporation is giving up on GED-0301 as a Crohn’s disease therapy, but will continue to evaluate its ability to treat ulcerative colitis. It ended its Phase 3 REVOLVE clinical trial (NCT02596893) and its SUSTAIN extension trial (NCT02641392) of GED-0301 as a potential Crohn’s treatment after an independent trial monitoring board recommended the discontinuations. The board had reviewed

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *